Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Long-acting (LA) injectable regimens are a potential therapeutic option in people living with HIV-1. SETTING: ATLAS (NCT02951052) and FLAIR (NCT02938520) were 2 randomized, open-label, multicenter, multinational phase 3 studies. METHODS: Adult participants with virologic suppression (plasma HIV-1 RN...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzardini, Giuliano, Overton, Edgar T., Orkin, Chloe, Swindells, Susan, Arasteh, Keikawus, Górgolas Hernández-Mora, Miguel, Pokrovsky, Vadim, Girard, Pierre-Marie, Oka, Shinichi, Andrade-Villanueva, Jaime F., Richmond, Gary J., Baumgarten, Axel, Masiá, Mar, Latiff, Gulam, Griffith, Sandy, Harrington, Conn M., Hudson, Krischan J., St. Clair, Marty, Talarico, Christine L., Patel, Parul, Cutrell, Amy, Van Eygen, Veerle, D'Amico, Ronald, Mrus, Joseph M., Wu, Sterling, Ford, Susan L., Chow, Ken, Roberts, Jeremy, Wills, Angela, Walters, Nicola, Vanveggel, Simon, Van Solingen-Ristea, Rodica, Crauwels, Herta, Smith, Kimberly Y., Spreen, William R., Margolis, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592884/
https://www.ncbi.nlm.nih.gov/pubmed/33136751
http://dx.doi.org/10.1097/QAI.0000000000002466

Ejemplares similares

Ejemplares similares